Entyvio®
INN: vedolizumab
Approved for use in:
Crohn’s Disease (moderate-severe)
Ulcerative Colitis (moderate-severe)
Type/Class
Originator Biologic
Delivery Route
Intravenous Infusion
Subcutaneous Injection
Health Canada Approval
2015
Storage
Refrigerate between 2 and 8°C, keep in original carton to protect from light, if needed the syringe can be left a room temperature for up to seven days, do not freeze, do not use after expiry date, do not use if you notice any particles or discolouration in the liquid prior to administration.
Use in Older Adults (65+)
May be used, please consult your doctor.
Pregnancy Indication
Effects not studied; women of reproductive potential recommended to use contraception during treatment and for at least 18 weeks after last dose.
Breastfeeding Indication
Effects unknown; please consult your doctor.
Pediatric Indication
Not recommended for use in children or adolescents (under 18 years of age).
Learn More
View the Entyvio® product monograph.